Two Funds.
One Research Platform.
KTR Capital manages two investment vehicles for accredited investors. Both are principal-led, both are supported by the same in-house research and technology infrastructure, and both are open to new investor relationships.
Biotechnology & Life Sciences
Open to accredited investors
The core of KTR’s mandate. Fund I takes long-term, high-conviction positions in U.S.-listed biotechnology and life-sciences equities, complemented by selective private investments in companies advancing oncology, biosensors, and advanced therapeutics.
Options Strategies
Powered by Helios
Currently raising capital
Fund II deploys systematic and discretionary options strategies driven by Helios, KTR’s proprietary options-market intelligence engine. Helios processes market, options, and macro data in real time — structuring dealer positioning and flow dynamics into the signals that inform entry, sizing, and risk.
What Qualified Investors Receive
We do not publish performance. We do share everything a serious allocator needs, in the order a serious allocator needs it.
Structure & Terms
Fund documents, fee terms, liquidity, and the service-provider stack — custody with J.P. Morgan Private Banking, administration by Mythos LLC.
Performance & Risk
Track record, exposure and drawdown history, and how each fund is sized and risk-managed day to day.
Research & Architecture
How Helios works, what it does and does not do, and where the firm’s research program is going next.
Begin the Conversation
Qualification, documentation, and onboarding for both funds are handled through KTR Investments.
Available to accredited investors only. This page is informational and does not constitute an offer or solicitation to invest. Offers are made solely through the applicable fund documents.